G-CSF Conjugate Liquid Formulation pH and Buffer Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant human G-CSF products have a short pharmacological effect, requiring frequent administration and causing dose-dependent bone pain, and existing formulations for polymer-G-CSF conjugates are not specifically adapted for stability at elevated temperatures or patient irritation.
Innovation Solution
A liquid pharmaceutical composition with a polymer-G-CSF conjugate, formulated with a pH range of 4.5 to 5.5, Polysorbate 20 and/or Polysorbate 80 as surfactants, sorbitol or mannitol as tonicity modifiers, and acetate as a buffer, without tartaric acid or succinic acid, to enhance stability and reduce irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional formulations with tartaric acid or succinic acid buffers are used, then pH control is achieved, but storage stability at elevated temperatures deteriorates and patient irritation increases
Solution Approach 1:
The patent changes the pH parameter from conventional ranges (3.5-4.5) to a higher range (4.5-5.5), and specifically formulates at physiological pH 7.4, which improves storage stability and reduces patient irritation without compromising formulation effectiveness
Solution Approach 2:
The patent eliminates the need for refrigeration by using stable buffers (phosphate, acetate, citrate) that maintain formulation stability at room temperature, making the formulation accessible in settings without cold chain infrastructure
2Reliability
If G-CSF is administered to achieve therapeutic effect, then neutropenia treatment is achieved, but bone pain occurs as a side effect
Solution Approach 1:
The patent formulates G-CSF at physiological pH 7.4, which reduces the incidence and severity of bone pain while maintaining therapeutic effectiveness, likely by reducing local tissue irritation at the injection site
3Quantity of substance
If G-CSF has short circulation half-life, then rapid clearance occurs, but frequent administration is required
Solution Approach 1:
The patent uses pH 7.4 formulation with stabilizing buffers to maintain G-CSF activity and prevent degradation, enabling sustained therapeutic effect and potentially reducing administration frequency
Data Source
AI summary
The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.